Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Passage Bio
Biotech
Spurned by FDA, Passage Bio finds exit through Remix
The proposed merger was announced in conjunction with an approximately $100 million private placement, and grants Remix a place on the Nasdaq.
Darren Incorvaia
Jun 24, 2026 5:20pm
Blocked by FDA, Passage cuts headcount by 75%
May 4, 2026 1:33pm
IGM, Y-mAbs, Passage Bio and more ring in 2025 with layoffs
Jan 10, 2025 2:44pm
Passage looks to offload lead program, 2 other assets
Dec 20, 2023 1:29pm
Stanford president resigns—Chutes & Ladders
Jul 21, 2023 9:30am
Passage decides 26% staff, 2 execs not needed on clinical voyage
Jul 21, 2023 6:25am
